

P&T Motion History Second Generation Antipsychotics

Drugs Reviewed	Motion	Date Reviewed	Scan Update Accepted as Adequate	Reiteration of Prior Motion	Decision
Aripiprazole Abilify MyCite Kit Aristada Initio Kit asenapine brexpiprazole cariprazine clozapine iloperidone lurasidone olanzapine paliperidone quetiapine risperidone Perseris Kit ziprasidone	After considering the evidence of safety, efficacy and special populations for the treatment of schizophrenia and bipolar disorder in adults and children, major depressive disorder in adults, and children and adolescents with Autism Spectrum Disorder (ASD) or disruptive behavior disorders, I move that all routes of administration for aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone are efficacious for their approved FDA indications and should be preferred on the Washington Preferred Drug List. Second Generation Antipsychotics cannot be subject to therapeutic interchange in the Washington preferred drug list. The preferred drug list should include at least one medication that is considered safe in pregnancy. Motion: Figueroa 2 nd : Karczewski	December 19, 2018	Yes Flatebo Figueroa	Yes Buccola Sanderson	Passed unanimous
		December 21, 2016	NA	No	Passed unanimous

Bold = new this update
12/20/2018